{"id":"NCT04716933","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study","officialTitle":"A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-05","primaryCompletion":"2023-08-11","completion":"2024-08-30","firstPosted":"2021-01-20","resultsPosted":"2024-10-04","lastUpdate":"2025-09-09"},"enrollment":201,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nonsquamous Non-small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Lenvatinib","otherNames":["MK-7902","E7080"]},{"type":"DRUG","name":"Placebo matching lenvatinib","otherNames":[]}],"arms":[{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL"},{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with metastatic nonsquamous non-small cell lung cancer.\n\nThe primary study hypotheses state that: 1) the combination of lenvatinib+platinum doublet chemotherapy+pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo+platinum doublet chemotherapy+pembrolizumab, and 2) the combination of lenvatinib+platinum doublet chemotherapy+pembrolizumab prolongs Overall Survival (OS) compared to matching placebo+platinum doublet chemotherapy + pembrolizumab.","primaryOutcome":{"measure":"Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 43 months","effectByArm":[{"arm":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","deltaMin":15.3,"sd":null},{"arm":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","deltaMin":9.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":26},"locations":{"siteCount":19,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":101},"commonTop":["Anaemia","Neutrophil count decreased","White blood cell count decreased","Aspartate aminotransferase increased","Alanine aminotransferase increased"]}}